



TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 4 July, 2024

In compliance with the disclosure duties set out in article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, "**ROVI**" or the "**Company**") informs the National Securities Market Commission as follows:

OTHER RELEVANT INFORMATION

Treasury share transactions under the Liquidity Contract in the second quarter of 2024

In relation to the current liquidity contract signed with Bestinver SV, S.A. in compliance with Circular 1/2017 of 26 April of the National Securities Market Commission on liquidity contracts, amended by Circular 2/2019 of 27 November, we set out below the transactions performed under said liquidity contract in the second quarter of 2024.

- **Securities account balance upon signature of the contract:** 88,495 shares.
- **Initial value of securities account:** 102,921 shares.
- **Purchases:** 37,355 shares.
- **Sales:** 47,907 shares.
- **Average price of purchases:** 85.66 euros.
- **Average price of sales:** 85.66 euros.
- **Final balance of securities account:** 92,369 shares.

- **Cash account balance upon signature of the contract:** 6,000,000.00 euros.
- **Initial balance of cash account:** 5,046,950.60 euros.
- **Cash relating to purchases:** 3,199,825.50 euros.
- **Cash relating to sales:** 4,103,816.80 euros.
- **Trading fees:** 1,236.80 euros.
- **Final balance of cash account:** 5,949,705.10 euros.

The list of transactions performed in the second quarter of 2024 is as follows:

Purchase/ Sale	Transaction date	No. securities	Block	No. transactions	Average price (€)	Cash (€)	Position at date (No. securities)	Net amount (€)
Purchase	12/06/2024	3,221	NO	62	88.04	- 283,567.100	106,142	4,763,383.50
Sale	12/06/2024	3,490	NO	69	87.88	306,715.650	102,652	5,070,099.15
Purchase	13/06/2024	3,482	NO	54	87.65	- 305,180.100	106,134	4,764,919.05
Sale	13/06/2024	3,480	NO	75	87.66	305,041.250	102,654	5,069,960.30
Purchase	14/06/2024	3,496	NO	100	86.35	- 301,893.150	106,150	4,768,067.15
Sale	14/06/2024	3,496	NO	58	86.03	300,766.250	102,654	5,068,833.40
Purchase	17/06/2024	3,545	NO	69	87.30	- 309,481.550	106,199	4,759,351.85
Sale	17/06/2024	3,550	NO	64	87.31	309,952.200	102,649	5,069,304.05
Purchase	18/06/2024	3,596	NO	69	85.31	- 306,789.650	106,245	4,762,514.40
Sale	18/06/2024	3,596	NO	59	85.31	306,788.800	102,649	5,069,303.20
Purchase	19/06/2024	3,695	NO	83	85.04	- 314,236.500	106,344	4,755,066.70
Sale	19/06/2024	3,694	NO	81	84.92	313,689.450	102,650	5,068,756.15
Purchase	20/06/2024	3,357	NO	50	85.58	- 287,283.850	106,007	4,781,472.30
Sale	20/06/2024	3,697	NO	57	85.51	316,144.750	102,310	5,097,617.05
Purchase	21/06/2024	3,596	NO	50	84.55	- 304,034.650	105,906	4,793,582.40
Sale	21/06/2024	3,596	NO	50	84.37	303,408.950	102,310	5,096,991.35
Purchase	24/06/2024	3,796	NO	84	83.10	- 315,460.300	106,106	4,781,531.05
Sale	24/06/2024	3,540	NO	75	82.81	293,131.400	102,566	5,074,662.45
Purchase	25/06/2024	2,294	NO	30	83.04	- 190,489.250	104,860	4,884,173.20
Sale	25/06/2024	3,544	NO	50	83.23	294,970.500	101,316	5,179,143.70
Purchase	26/06/2024	1,904	NO	27	85.80	- 163,361.000	103,220	5,015,782.70
Sale	26/06/2024	3,758	NO	60	84.91	319,103.250	99,462	5,334,885.95
Purchase	27/06/2024	1,273	NO	17	85.95	- 109,418.400	100,735	5,225,467.55
Sale	27/06/2024	4,170	NO	72	86.41	360,344.050	96,565	5,585,811.60
Purchase	28/06/2024	100	NO	2	86.30	- 8,630.000	96,665	5,577,181.60
Sale	28/06/2024	4,296	NO	88	87.00	373,760.300	92,369	5,950,941.90
Trading fees								-1,236.80
TOTAL		-10,552				903,991.30	92,369	5,949,705.10

Mr Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos Rovi, S.A.